329 related articles for article (PubMed ID: 36415148)
41. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
42. Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3.
Shih PC; Naganuma M; Tsuji G; Demizu Y; Naito M
Bioorg Med Chem; 2023 Nov; 95():117507. PubMed ID: 37922656
[TBL] [Abstract][Full Text] [Related]
43. Developments of PROTACs technology in immune-related diseases.
Wang C; Zhang Y; Deng J; Liang B; Xing D
Eur J Med Chem; 2023 Mar; 249():115127. PubMed ID: 36724631
[TBL] [Abstract][Full Text] [Related]
44. PROTACs: An Emerging Therapeutic Modality in Precision Medicine.
Nalawansha DA; Crews CM
Cell Chem Biol; 2020 Aug; 27(8):998-1014. PubMed ID: 32795419
[TBL] [Abstract][Full Text] [Related]
45. Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance.
Zhu H; Wang J; Zhang Q; Pan X; Zhang J
Pharmacol Ther; 2023 Apr; 244():108371. PubMed ID: 36871783
[TBL] [Abstract][Full Text] [Related]
46. Expanding PROTACtable genome universe of E3 ligases.
Liu Y; Yang J; Wang T; Luo M; Chen Y; Chen C; Ronai Z; Zhou Y; Ruppin E; Han L
Nat Commun; 2023 Oct; 14(1):6509. PubMed ID: 37845222
[TBL] [Abstract][Full Text] [Related]
47. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.
Diehl CJ; Ciulli A
Chem Soc Rev; 2022 Oct; 51(19):8216-8257. PubMed ID: 35983982
[TBL] [Abstract][Full Text] [Related]
48. Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin-Proteasome system.
Xie H; Zhang C
Eur J Med Chem; 2024 Mar; 267():116168. PubMed ID: 38310686
[TBL] [Abstract][Full Text] [Related]
49. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
Pettersson M; Crews CM
Drug Discov Today Technol; 2019 Apr; 31():15-27. PubMed ID: 31200855
[TBL] [Abstract][Full Text] [Related]
50. Proteasomal Degradation of Zn-Dependent Hdacs: The E3-Ligases Implicated and the Designed Protacs That Enable Degradation.
Márquez-Cantudo L; Ramos A; Coderch C; de Pascual-Teresa B
Molecules; 2021 Sep; 26(18):. PubMed ID: 34577077
[TBL] [Abstract][Full Text] [Related]
51. In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs).
Tomoshige S; Ishikawa M
Bioorg Med Chem; 2021 Jul; 41():116221. PubMed ID: 34034148
[TBL] [Abstract][Full Text] [Related]
52. PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas.
Mancarella C; Morrione A; Scotlandi K
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003535
[TBL] [Abstract][Full Text] [Related]
53. Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic.
Hu Z; Crews CM
Chembiochem; 2022 Jan; 23(2):e202100270. PubMed ID: 34494353
[TBL] [Abstract][Full Text] [Related]
54. Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges.
Yang W; Saboo S; Zhou L; Askin S; Bak A
Drug Discov Today; 2024 Feb; 29(2):103865. PubMed ID: 38154757
[TBL] [Abstract][Full Text] [Related]
55. New Frontiers in the Discovery and Development of PROTACs.
Barghout SH
Anticancer Agents Med Chem; 2022 Aug; 22(15):2656-2661. PubMed ID: 35418290
[TBL] [Abstract][Full Text] [Related]
56. Advancing targeted protein degradation for metabolic diseases therapy.
Zhou QQ; Xiao HT; Yang F; Wang YD; Li P; Zheng ZG
Pharmacol Res; 2023 Feb; 188():106627. PubMed ID: 36566001
[TBL] [Abstract][Full Text] [Related]
57. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.
Burslem GM; Crews CM
Cell; 2020 Apr; 181(1):102-114. PubMed ID: 31955850
[TBL] [Abstract][Full Text] [Related]
58. PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities.
Liu X; Wang A; Shi Y; Dai M; Liu M; Cai HB
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770884
[TBL] [Abstract][Full Text] [Related]
59. Advances in AR-targeting chimeras: a case study of proteolysis-targeting chimeras from bench to bedside.
Du W
Future Med Chem; 2022 Oct; 14(20):1471-1489. PubMed ID: 36214138
[TBL] [Abstract][Full Text] [Related]
60. E3 ligase ligand chemistries: from building blocks to protein degraders.
Sosič I; Bricelj A; Steinebach C
Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
